查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1970830

全球人类乳突病毒疫苗市场规模、份额、趋势和成长分析报告（2026-2034年）

Global Human Papillomavirus Vaccine Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 141 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计人类乳突病毒疫苗市场将从 2025 年的 96.6 亿美元成长到 2034 年的 210.9 亿美元，2026 年至 2034 年的复合年增长率为 9.06%。

随着免疫接种计画在已开发经济体和新兴经济体中日益重要，全球人类乳突病毒（HPV）疫苗市场正经历加速成长。政府主导的各项措施不断扩大，民众对HPV相关癌症的认识不断提高，以及透过公私合营改善疫苗取得途径，都推动了疫苗接种率的提升。生物技术的进步，包括耐热配方和新一代佐剂系统，正在克服低温运输限制，提高疫苗效力，并改善资源匮乏地区疫苗宣传活动的成效。

对更广泛的人类乳突病毒(HPV)疫苗的持续研究正在改变竞争格局。推动开发涵盖更多致癌性病毒株的多价疫苗製剂，将显着增强疫苗策略的长期影响。同时，将人类乳突病毒(HPV)疫苗纳入国家免疫规划，并整合用于监测和合规性的数位化健康平台，正在加强机构的采纳。此外，製药公司正在优先发展可扩展的生产平台，例如重组DNA技术和细胞培养系统，从而降低成本并增加供应。

展望未来，生物製药公司、诊断公司和公共卫生机构之间的合作将推动HPV预防的综合办法。疫苗与人工智慧驱动的流行病学模型、精准公共卫生框架和全球宣传宣传活动的整合有望进一步提高疫苗接种率。随着医疗保健、公平取得和个人化免疫接种方案变得日益重要， 人类乳突病毒(HPV)疫苗市场将继续扩大，成为全球癌症防治策略的基础。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章：全球人类乳突病毒疫苗市场：依类型划分

  • 市场分析、洞察与预测
  • 二价
  • 四价
  • 九价

第五章 全球人类乳突病毒疫苗市场：依疾病分类

  • 市场分析、洞察与预测
  • 子宫颈癌
  • 阴道癌及外阴癌
  • 肛门癌
  • 口腔和咽喉（头颈部）癌
  • 生殖器湿疣

第六章：全球人类乳突病毒疫苗市场：依分销管道划分

  • 市场分析、洞察与预测
  • 医院和零售药局
  • 政府采购承包商
  • 其他的

第七章 全球人类乳突病毒疫苗市场：依地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第八章 竞争情势

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第九章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • Merck & Co. Inc
    • GlaxoSmithKline Plc（GSK）
    • Serum Institute Of India Pvt. Ltd
    • Sanofi Pasteur SA
    • Pfizer Inc
    • Inovio Pharmaceuticals Inc
    • Walvax Biotechnology Co. Ltd
    • Bharat Biotech International Ltd
    • Johnson & Johnson Services Inc
    • Moderna Inc
    • Gilead Sciences Inc
简介目录
Product Code: VMR112111434

The Human Papillomavirus Vaccine Market size is expected to reach USD 21.09 Billion in 2034 from USD 9.66 Billion (2025) growing at a CAGR of 9.06% during 2026-2034.

The global human papillomavirus vaccine market is positioned for accelerated growth as immunization programs gain prominence across both developed and emerging economies. Expanding government-led initiatives, rising awareness of HPV-related cancers, and increasing accessibility of vaccines through public-private partnerships are driving adoption rates. Biotechnology advances, including thermostable formulations and next-generation adjuvant systems, are addressing cold-chain limitations and enhancing efficacy, making vaccination campaigns more effective in resource-constrained regions.

Continuous research into broader-spectrum HPV vaccines is reshaping the competitive landscape. The push for multivalent formulations that cover an expanded range of oncogenic strains will significantly boost the long-term impact of vaccination strategies. Meanwhile, integration of HPV vaccines into national immunization schedules, coupled with digital health platforms for monitoring and compliance, is reinforcing systemic adoption. Additionally, pharmaceutical manufacturers are prioritizing scalable production platforms such as recombinant DNA technologies and cell-based systems, allowing for cost reduction and expanded supply availability.

In the future, collaborations between biopharma companies, diagnostic firms, and public health agencies will drive a holistic approach to HPV prevention. The growing convergence of vaccines with AI-driven epidemiological modeling, precision public health frameworks, and global awareness campaigns will intensify uptake. With rising emphasis on preventive healthcare, equitable access, and personalized immunization schedules, the HPV vaccine market will continue to expand as a cornerstone of global cancer control strategies.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Bivalent
  • Quadrivalent
  • Nonavalent

By Disease

  • Cervical Cancer
  • Vaginal and Vulvar Cancers
  • Anal Cancer
  • Oropharyngeal (Head and Neck) Cancers
  • Genital Warts

By Distribution Channel

  • Hospitals and Retail Pharmacies
  • Government Suppliers
  • Others

COMPANIES PROFILED

  • Merck Co Inc, GlaxoSmithKline plc GSK, Serum Institute of India Pvt Ltd, Sanofi Pasteur SA, Pfizer Inc, Inovio Pharmaceuticals Inc, Walvax Biotechnology Co Ltd, Bharat Biotech International Ltd, Johnson Johnson Services Inc, Moderna Inc, Gilead Sciences Inc
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Bivalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.3. Quadrivalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.4. Nonavalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: BY DISEASE 2022-2034 (USD MN and Million Doses)

  • 5.1. Market Analysis, Insights and Forecast Disease
  • 5.2. Cervical Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.3. Vaginal and Vulvar Cancers Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.4. Anal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.5. Oropharyngeal (Head and Neck) Cancers Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.6. Genital Warts Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Million Doses)

  • 6.1. Market Analysis, Insights and Forecast Distribution Channel
  • 6.2. Hospitals and Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.3. Government Suppliers Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: BY REGION 2022-2034(USD MN and Million Doses)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.2.1 By Type
    • 7.2.2 By Disease
    • 7.2.3 By Distribution Channel
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.3.1 By Type
    • 7.3.2 By Disease
    • 7.3.3 By Distribution Channel
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.4.1 By Type
    • 7.4.2 By Disease
    • 7.4.3 By Distribution Channel
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.5.1 By Type
    • 7.5.2 By Disease
    • 7.5.3 By Distribution Channel
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.6.1 By Type
    • 7.6.2 By Disease
    • 7.6.3 By Distribution Channel
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL HUMAN PAPILLOMAVIRUS VACCINE INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Merck & Co. Inc
    • 9.2.2 GlaxoSmithKline Plc (GSK)
    • 9.2.3 Serum Institute Of India Pvt. Ltd
    • 9.2.4 Sanofi Pasteur SA
    • 9.2.5 Pfizer Inc
    • 9.2.6 Inovio Pharmaceuticals Inc
    • 9.2.7 Walvax Biotechnology Co. Ltd
    • 9.2.8 Bharat Biotech International Ltd
    • 9.2.9 Johnson & Johnson Services Inc
    • 9.2.10 Moderna Inc
    • 9.2.11 Gilead Sciences Inc